CUE
HEALTHCARECue Biopharma
AI Insight
What's Moving CUE Today?
No stock-specific AI insight has been generated for CUE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.97$41.42
$26.90
Fundamentals
Market Cap$129M
P/E Ratio—
EPS$-4.53
Dividend Yield—
Dividend / Share—
ROE-138.5%
Profit Margin-59.7%
Debt / Equity—
Trading
Volume93K
Avg Volume (10D)—
Shares Outstanding4.2M
CUE News
23 articles- Cue Biopharma (CUE) director awarded 1,626 stock options at $21.90 strikeStock Titan·Jun 9, 2026
- Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company EvolutionYahoo Finance·Jun 2, 2026
- Cue Biopharma to Present at the 2026 Jefferies Global Healthcare ConferenceYahoo Finance·May 21, 2026
- Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic DevelopmentsYahoo Finance·May 14, 2026
- New Cue Biopharma CEO gets 655,074-share option and 327,537 stock unitsStock Titan·May 7, 2026
- Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire·May 7, 2026
- Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·May 7, 2026
- Cue Biopharma Announces $30 Million Private PlacementYahoo Finance·Apr 30, 2026
- Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE AntibodyYahoo Finance·Apr 30, 2026
- Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage CompanyYahoo Finance·Apr 30, 2026
- Cue Biopharma Announces 1-for-30 Reverse Stock SplitYahoo Finance·Apr 22, 2026
- Cue Biopharma (CUE) Appoints Lucinda Warren as Interim President and CEOYahoo Finance·Apr 20, 2026
- Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026Yahoo Finance·Apr 15, 2026
- The VIX Sharply Reverses and Points Back Towards 30 After Failed Peace Negotiations247 Wall St·Apr 13, 2026
- Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License AgreementGlobeNewswire Inc.·Apr 8, 2026
- Cue Biopharma Announces CEO TransitionYahoo Finance·Mar 27, 2026
- Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026Yahoo Finance·Mar 26, 2026
- Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsYahoo Finance·Mar 16, 2026
- Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026Yahoo Finance·Mar 9, 2026
- Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory DiseasesYahoo Finance·Feb 17, 2026
- Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business OfficerYahoo Finance·Feb 12, 2026
- Cue Biopharma Announces Pricing of $10 Million Public OfferingYahoo Finance·Dec 19, 2025
- Cue Biopharma Announces Proposed Public OfferingYahoo Finance·Dec 18, 2025
All 23 articles loaded
Price Data
Open$30.25
Previous Close$30.73
Day High$30.56
Day Low$25.80
52 Week High$41.42
52 Week Low$4.97
52-Week Range
$4.97$41.42
$26.90
Fundamentals
Market Cap$129M
P/E Ratio—
EPS$-4.53
Dividend Yield—
Dividend / Share—
ROE-138.5%
Profit Margin-59.7%
Debt / Equity—
Trading
Volume93K
Avg Volume (10D)—
Shares Outstanding4.2M
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biological drugs for the selective modulation of the human immune system to treat a variety of cancers, chronic infectious diseases, and autoimmune disorders. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—